Investor Presentaiton

ASCEND Clinical Trial Program The Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat (ASCEND) Phase III program investigated the efficacy and safety profile of daprodustat across Dialysis trials ascend DIALYSIS a spectrum of patients with CKD Cardiovascular Outcome Trials (CVOTS) Non-dialysis trials asceND ND NON-DIALYSIS asceNDID INCIDENT DIALYSIS asceND TD THREE-TIMES WEEKLY DOSING IN DIALYSIS ASCEND Phase III Program Com asceND/NHQ NON-DIALYSIS, HEMOGLOBIN & QUALITY OF LIFE CKD, chronic kidney disease; D dialysis; Hb, hemoglobin; ID, incident dialysis; ND, non-dialysis; NHQ, TD, three times a week dosing. 8

View entire presentation